Cost‐Effectiveness of Tailored vs. Empirical Therapy for H. pylori : A Decision‐Tree Analysis
Helicobacter · 2025
DOI: 10.1111/hel.70081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Helicobacter, 2025. Verfasst von Joon Sung Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Anti-Bacterial Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Patient-Centered Clinical Research Coordinating Center, Ministry of Health.
Abstract (Originalsprache)
Background
In Korea, tailored therapy for H. pylori based on clarithromycin resistance has been shown to be more effective than empirical therapy. However, the cost‐effectiveness of tailored therapy has not yet been fully established.
Aim
This study evaluated the cost‐effectiveness of tailored therapy guided by genotypic resistance compared to empirical clarithromycin‐based triple therapy.
Methods
A decision‐tree model was developed to compare two treatment strategies: empirical therapy and tailored therapy. In the empirical therapy group, patients received clarithromycin‐based triple therapy. In the tailored therapy group, patients susceptible to clarithromycin received clarithromycin‐based triple therapy, while those with clarithromycin resistance were treated with bismuth‐based quadruple therapy. A cost‐effectiveness analysis was conducted, and the incremental cost‐effectiveness ratio (ICER) was calculated to compare the two strategies.
Results
The estimated costs for empirical and tailored therapies were $173.93 and $249.48, respectively. Compared to empirical therapy, the ICER for tailored therapy was $4.66 per 1% increase in eradication rate, representing the additional cost required to achieve a 1% improvement in eradication. In subgroup analyses, the estimated costs of 7‐day empirical and tailored therapies were $157.46 and $233.88, respectively, while the costs for 14‐day empirical and tailored therapies were $190.40 and $265.08, respectively. The ICERs for the 7‐ and 14‐day regimens were $3.53 and $7.12, respectively.
Discussion
Tailored therapy guided by genotypic resistance is a cost‐effective strategy for H. pylori eradication in Korea, particularly in the context of high clarithromycin resistance rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- College of Pharmacy, Ewha Womans University, Seoul, Republic of Korea.
- Department of Biohealth Regulatory Science, Graduate School of Ajou University, Suwon, Republic of Korea.
ORCID-Profile: Joon Sung Kim, Byung-Wook Kim
Förderung
- Patient-Centered Clinical Research Coordinating Center
- Ministry of Health
Zitieren
APA
Kim, J. S., Lee, H., Jeong, Y., & Kim, B. W. (2025). Cost‐Effectiveness of Tailored vs. Empirical Therapy for H. pylori : A Decision‐Tree Analysis. Helicobacter. https://doi.org/10.1111/hel.70081
Vancouver
Kim JS, Lee H, Jeong Y, Kim BW. Cost‐Effectiveness of Tailored vs. Empirical Therapy for H. pylori : A Decision‐Tree Analysis. Helicobacter. 2025. doi:10.1111/hel.70081
BibTeX
@article{Kim2025,
author = {Kim, Joon Sung and Lee, Hankil and Jeong, Yuri and Kim, Byung-Wook},
title = {Cost‐Effectiveness of Tailored vs. Empirical Therapy for H. pylori : A Decision‐Tree Analysis},
journal = {Helicobacter},
year = {2025},
doi = {10.1111/hel.70081}
}
EUVIMED